



# Vaccine Innovations

## Walvax's mRNA Vaccine Platform for COVID-19 Variant Vaccine

Andrew Wong, MD, MBA  
General Manager, Wotai Biotechnology Co. Ltd., a Walvax company

21 September 2023

## Walvax: A Leading Vaccine Developer & Producer in China

Walvax is one of China's most innovative and highest revenue generating companies for self-developed and produced vaccines, and ranked the world's **8<sup>th</sup>** manufacturer by value in 2021 by WHO.



### Key Financials

**Market Cap:**  
**5.3 billion** USD  
(September 1, 2023)

**2022 Revenue:**  
**747.9 million** USD  
(46.9% growth over 2021)

**Manufacturers by Value:**  
**Top 8** in 2021  
(by WHO, excluding Covid vaccines)



### Vaccine Products

**8** licensed products  
**3** candidates in clinical stage  
**74** patents  
**18** countries exported to  
**3 vaccines** in Morocco, Indonesia and Egypt **EPIs**



### Collaborations

**1<sup>st</sup>** private Chinese vaccine company funded by Bill & Melinda Gates Foundation and CEPI  
**3** regional manufacturing partnerships in Morocco, Indonesia and Egypt



### Talents

**~ 2000 employees:**  
PhD and Master: ~200 staff  
Manufacture: 71%  
General & Admin: 15%  
R&D: 8%  
Sales: 6%

## Fast Response mRNA Platform

By collaborating with Fudan University and RNACure and through Covid-19 vaccine R&D, Walvax has established a mRNA platform with 62-day lead time from DNA sequence to the first batch of sample.



Vaccine designed	Code of the mRNA Vaccine	Stage
mRNA Vaccine (1 strand)	RQ3013 (alpha + beta variant chimera)	BLA filing
	RQ3019 (Omicron.2/4/5)	-
	RQ3033 (XBB.1.5)	IND
mRNA Vaccine (2 strands)	RQ3025 (RQ3013+RQ3019)	IND

## SARS-CoV-2 variant mRNA vaccine (RQ3013) : Target Product Profile

<b>Antigen</b>	mRNA chimera of SARS-CoV-2 alpha and beta variants spike protein
<b>Administration Route</b>	Intramuscular injection
<b>Indication</b>	Prevention of COVID-19 caused by the infection of SARS-CoV-2
<b>Target Population</b>	18 years and older
<b>Schedule</b>	Primary series: 2-dose at Day 0 and Day 28 Booster dose: a single dose at least 6 months following the last COVID-19 vaccine
<b>Presentation</b>	30 µg mRNA/0.15 mL/dose, single dose vial
<b>Self life &amp; Storage</b>	12 month, store at -20 °C or below

## RQ3013 Clinical Development Program





## Manufacturing Readiness

### Facilities ready

240 million doses/year



### Under construction

480 million/year



## Summary

---

- Walvax has established mRNA vaccine R&D and manufacturing platform through Covid-19 vaccine, fully validated its feasibility and fast response capability to encounter emerging Covid-19 variant endemics.
- This mRNA development platform will enable Walvax to develop more mRNA vaccines against other deadly infectious diseases and contribution more to global health.

Andrew Wong  
[andrew.wong@walvax.com](mailto:andrew.wong@walvax.com)



Walvax Biotechnology Co., Ltd.



Pudong, Shanghai, China  
Kunming, Yunnan, China



[en.walvax.com](http://en.walvax.com)

**WALVAX**